Omnicare, Inc. (OCR)
A geriatric pharmaceutical services company, which provides pharmaceuticals and related ancillary pharmacy services to long-term healthcare institutions. Operates in two business segments: Pharmacy Services and Contract Research Organization Services.
Recs
IAM2XL
(< 20)
Submitted: 9/24/2009 10:07:05 AM :
Start Price:
$23.28
OCR Score:
-3.62
I see so many old people shuffling about...
Recs
clarkrl2
(61.83)
Submitted: 9/13/2009 5:24:59 PM :
Start Price:
$23.74
OCR Score:
-8.38
At 23.89 the stock is well off its 52 week high of 32.54. The earnings estimates for 2009 and 2010 are much higher than the current earnings of 1.27 and the forward PE is only 8.85 which is very good compared to the 5-year earnings growth estimate of 13. The MSN stock scouter rating is 7. My initial target is about 34% above its current price.
Recs
gnaltieri
(< 20)
Submitted: 8/5/2009 9:50:08 AM :
Start Price:
$23.70
OCR Score:
-12.52
Being a sizable stockholder for 13 years I am certainly in hopes that it finally catches up with my cost (34.50) 13 years ago. Come on everybody buy some.
Recs
RXDOC73
(99.18)
Submitted: 8/3/2009 12:36:37 PM :
Start Price:
$23.59
OCR Score:
-11.62
Good balance sheet and also good acquisition target.
Recs
00100
(96.79)
Submitted: 7/28/2009 8:17:45 PM :
Start Price:
$27.00
OCR Score:
-27.17
Upthumb. Good cash flow. Low payout ratio. Good growth rate (11%); nominal to low debt ratio. Good margins. Good management. Takeover play.
Recs
mickyo77
(< 20)
Submitted: 7/16/2009 4:48:05 PM :
Start Price:
$19.17
OCR Score:
+39.34
They have new folks at Corporate level replacing some dogs that were in management earlier that were greedy.
Recs
BSHumphreyII
(87.18)
Submitted: 4/28/2009 2:19:50 PM :
Start Price:
$26.92
OCR Score:
-42.08
Omnicare has a good balance sheet, is priced under book value, and is in a solid industry with inelastic markets. Add to that the potential for a takeover by Walgreens, and this one looks good.
Recs
agentscarn
(21.45)
Submitted: 3/11/2009 4:39:20 PM :
Start Price:
$23.92
OCR Score:
-56.68
net income growth by 37%
Recs
skyprince60
(21.71)
Submitted: 11/13/2008 2:37:38 PM :
Start Price:
$24.17
OCR Score:
-32.09
Well run company in a growing space that is on sale at incredible low price.
Recs
oxsigtech
(< 20)
Submitted: 7/31/2008 12:38:08 PM :
Start Price:
$28.74
OCR Score:
-7.96
Old people need drugs.
Recs
GoyangDangdut
(< 20)
Submitted: 6/25/2008 4:42:46 AM :
Start Price:
$24.54
OCR Score:
+8.60
OCR will anooune its earning that historical has gowth in relative strength
Recs
grammatoncleric
(66.17)
Submitted: 3/12/2008 1:10:14 PM :
Start Price:
$16.93
OCR Score:
-50.75
health care
Recs
doggetla
(< 20)
Submitted: 11/7/2007 7:09:33 AM :
Start Price:
$26.62
OCR Score:
+10.74
OCR will be one of the surprising 3 star stocks. current very undervalued IV of 54.00
pay a small dividend for your wait.
oh!! by the way america is getting OLDER!!!!!
old age more drugs, keep your cost down buy generic, equals OCR
Recs
chitownjester
(48.88)
Submitted: 9/20/2007 5:32:39 PM :
Start Price:
$30.34
OCR Score:
+1.19
Market reactions overblown. Capitalizing on long-term irreversable trend called "getting older". Americans don't want to take care of their own aging family members, so they will end up in assisted living with companies like OCR making a nice profit for related services.
Recs
DeepSouthValue
(< 20)
Submitted: 9/7/2007 11:01:09 AM :
Start Price:
$30.67
OCR Score:
-3.57
love those monopolies
Recs
holopoj
(57.30)
Submitted: 8/27/2007 12:19:44 PM :
Start Price:
$32.72
OCR Score:
-7.47
Looks way undervalued compared to historical P/E
Recs
wgscogen
(< 20)
Submitted: 5/12/2007 3:25:45 PM :
Start Price:
$35.22
OCR Score:
-11.00
market over-reacting to bad news. OCR will return to form and expect a nice bounce
Recs
gavinsblog
(< 20)
Submitted: 4/30/2007 1:08:03 PM :
Start Price:
$33.35
OCR Score:
-7.96
Unwarranted fall, IV.
Recs
pomskua
(21.33)
Submitted: 4/27/2007 11:17:53 AM :
Start Price:
$35.52
OCR Score:
-12.42
Entering during what I think is an overreaction to poor Q1 results. This leading company is in a field where aging boomers will be a driving factor for decades.
Recs
kleiv
(< 20)
Submitted: 3/5/2007 2:31:27 PM :
Start Price:
$38.49
OCR Score:
-23.72
A near monopoly in institutional pharmecueticals. Top line growth along with margin improvement over the next 2 years. Problems of late are temporary, have nothing to do with long term viability of the business.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 34 1 2 Next »